Highly efficient synthesis and monoamine oxidase B inhibitory profile of demethyleneberberine, columbamine and palmatine
| Autor: | Guo-zhen Cui, Jian Chen, Min Ma, Cheng Tao, Sheng-quan Hu, Yuan-ji Chen, Zheng-zhi Wu, Ke-huan Sun |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Monoamine Oxidase Inhibitors Berberine Berberine Alkaloids 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Biosynthesis Humans Monoamine Oxidase IC50 Demethylation chemistry.chemical_classification Binding Sites Dose-Response Relationship Drug Plant Extracts Chemistry Palmatine Cell Biology 030104 developmental biology Enzyme Biochemistry Monoamine oxidase B 030217 neurology & neurosurgery |
| Zdroj: | Neurochemistry International. 139:104807 |
| ISSN: | 0197-0186 |
| DOI: | 10.1016/j.neuint.2020.104807 |
| Popis: | The biosynthesis of berberine alkaloids is thought to begin with the demethylation of berberine followed by methylation reactions to generate other type berberine alkaloids. This seemingly expeditious way to access berberine alkaloids has been stagnated for over half a century due to certain vexing synthetic problems, such as low isolated yield, complex operations and toxic reagents. We further investigated this bioinspired semi-synthesis strategy and significantly improved the synthetic efficacy, by providing a practical synthetic process for demethyleneberberine (DMB), columbamine and palmatine. Furthermore, we found that DMB (IC50, 9.06 μM) inhibited the activity of monoamine oxidase B (MAO-B), an enzyme that deaminates dopamine and is particularly involved in the pathology of Parkinson's disease. Besides, columbamine was able to decrease MAO-B activity by approximately 40%. These findings provide perquisites for further in vivo investigation to confirm the therapeutic potentiality of berberine alkaloids, DMB in particular. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect